Does triple negative breast cancer influence your decision to boost an older patient post lumpectomy?

Yes. The phenotype of breast cancer does predict the risk of relapse in the elderly population as well. For that reason, we would offer a boost in all triple negative patients, irrespective of age. In a recent update of the Toronto–British Columbia (TBC) randomized study for older patients with node...

Yes. The pathologic subanalysis of the EORTC boost trial clearly demonstrated a more substantial benefit from a tumor bed boost in patients with high grade disease. I think it is reasonable to extrapolate this finding to indicate that a boost is likely to be beneficial in triple negative disease, as...